BioSpace - Print News Article

NPS Pharmaceuticals (NPSP) And Ventiv Health, Inc. (VTIV) Announce The Launch Of A Specialty Sales Force 10/19/2005 5:12:55 PM SALT LAKE CITY and SOMERSET, N.J., March 3 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) and Ventiv Health, Inc. (Nasdaq: VTIV), announced today that they have introduced a specialized sales team to promote Kineret(R) (anakinra), a biologic therapy owned by Amgen Inc., for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in adult patients who have failed one or more disease modifying antirheumatic drugs. Under an agreement with Amgen, NPS is the exclusive representative of the drug to rheumatologists in the U.S.

NPS Pharmaceuticals (NPSP) And Ventiv Health, Inc. (VTIV) Announce The Launch Of A Specialty Sales Force
10/19/2005 5:12:55 PM

SALT LAKE CITY and SOMERSET, N.J., March 3 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) and Ventiv Health, Inc. (Nasdaq: VTIV), announced today that they have introduced a specialized sales team to promote Kineret(R) (anakinra), a biologic therapy owned by Amgen Inc., for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in adult patients who have failed one or more disease modifying antirheumatic drugs. Under an agreement with Amgen, NPS is the exclusive representative of the drug to rheumatologists in the U.S.